• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Choroidal Neovascularization

Choroidal Neovascularization - 17 Studies Found

Completed : AVENUE: A Proof-of-Concept Study of RG7716 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
: Macular Degeneration, Choroidal Neovascularization
: 2015-06-12
:
  • Drug: RG7716 Participants will

Completed : Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
:
  • Macular Degeneration
  • Choroidal Neovascularization

: 2007-02-16
:
  • Drug: Verteporfin Photodynamic Therapy

Completed : A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
: Choroidal Neovascularization Secondary to Pathologic Myopia
: 2014-01-09
: Drug: Ranibizumab All patients will receive a single initial intravitreal injection of ranibizumab 0.5 m
Completed : Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration
:
  • Choroidal Neovascularization
  • Macular Degeneration

: 1999-11-03
: Drug: Corticosteroid
Completed : An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO
: Choroidal Neovascularization, Age-related Macular Degeneration
: 2006-09-21
: Drug: Ranibizumab 0.5 mg Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an
Terminated : Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
:
  • Macular Degeneration
  • Choroidal Neovascularization

: 2007-02-08
:
  • Drug: Verteporfin Photodynamic Therapy

Completed : Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients
: Idiopathic Choroidal Neovascularization
: 2014-10-02
: Drug: aflibercept The patients are followed on a monthly basis until 52 weeks. Intravitreal injections o
<<< Previous
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.